How to take Mirvetuximab soravtansine-gynx

The recommended dose of Mirvetuximab soravtansine-gynx is 6 mg/kg adjusted ideal body weight (AIBW) as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. If a patient experiences adverse reactions after taking mivituximab, the doctor will adjust the dose as follows; the first dose will be reduced to 5 mg/kg adjusted ideal body weight (AIBW); the second dose will be reduced to 4 mg/kg adjusted ideal body weight (AIBW); patients who cannot tolerate 4 mg/kg AIBW should permanently discontinue the drug.

The total dose of milvituximab was calculated based on each patient'sAIBW using the following formula:

AIBW=ideal weight (IBW[kg])+0.4*(actual weight[kg]-IBW);

FemaleIBW (kg) = 0.9 * Height (cm) -92.

Doctors will select mivituximab to treat patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer based on the presence of FR-α tumor expression. Before initiating mivituximab, perform ophthalmic examinations, including visual acuity and slit-lamp examination, every other cycle for the first 8 cycles as clinically indicated. One day before each infusion of milvituximab, doctors may prescribe premedication, including corticosteroids, antihistamines, antipyretics, antiemetics, etc., to reduce the incidence and severity of infusion-related reactions (IRRs), nausea, and vomiting.

Since milvituximab has been on the market for a short time, there may be less information on its price and other related information.